Contract research firm Inotiv's Q1 operating loss widens

Overview

• Contract research firm's fiscal Q1 2026 revenue rose 0.8% yr/yr

• Adjusted EBITDA for fiscal Q1 2026 missed analyst expectations

• Company exited two leased facilities as part of site optimization plan

Outlook

• Company did not provide specific guidance for future quarters or full year

Result Drivers

• DSA REVENUE GROWTH - DSA segment revenue increased by 12% due to higher demand for discovery pharmacology and safety assessment services

• RMS REVENUE DECLINE - RMS segment revenue decreased by 5.4%, primarily due to lower non-human primate volumes sold

• OPERATING LOSS INCREASE - Operating loss increased due to higher costs in RMS segment despite some cost reductions

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Inotiv Inc is $2.75, about 557.4% above its February 6 closing price of $0.42

Press Release: ID:nGNX6nHM0x

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.